On Sung-Woon, Park Sang-Yoon, Yi Sang-Min, Park In-Young, Byun Soo-Hwan, Yang Byoung-Eun
Division of Oral and Maxillofacial Surgery, Department of Dentistry, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong 18450, Republic of Korea.
Department of Artificial Intelligence and Robotics in Dentistry, Graduated School of Clinical Dentistry, Hallym University, Chuncheon 24252, Republic of Korea.
Bioengineering (Basel). 2023 Aug 24;10(9):1005. doi: 10.3390/bioengineering10091005.
Recombinant human bone morphogenetic protein-2 (rhBMP-2) has shown potential in maxillofacial surgery owing to its osteoinductive properties. However, concerns about its safety and high cost have limited its widespread use. This review presents the status of rhBMP-2 use in maxillofacial surgery, focusing on its clinical application, efficacy, safety, and limitations. Studies have demonstrated rhBMP-2's potential to reduce donor site morbidity and increase bone height in sinus and ridge augmentation; however, it may not outperform autogenous bone grafts. In medication-related osteonecrosis of the jaw treatment, rhBMP-2 has been applied adjunctively with promising results, although its long-term safety requires further investigation. However, in maxillofacial trauma, its application is limited to the restoration of large defects. Safety concerns include postoperative edema and the theoretical risk of carcinogenesis. Although postoperative edema is manageable, the link between rhBMP-2 and cancer remains unclear. The limitations include the lack of an ideal carrier, the high cost of rhBMP-2, and the absence of an optimal dosing regimen. In conclusion, rhBMP-2 is a promising graft material for maxillofacial surgery. However, it has not yet become the gold standard owing to safety and cost concerns. Further research is required to establish long-term safety, optimize dosing, and develop better carriers.
重组人骨形态发生蛋白-2（rhBMP-2）因其骨诱导特性在颌面外科手术中显示出潜力。然而，对其安全性和高成本的担忧限制了其广泛应用。本综述介绍了rhBMP-2在颌面外科手术中的应用现状，重点关注其临床应用、疗效、安全性和局限性。研究表明，rhBMP-2有潜力降低供区发病率，并增加鼻窦和牙槽嵴增高术中的骨高度；然而，它可能并不比自体骨移植更具优势。在颌骨药物相关性骨坏死的治疗中，rhBMP-2已作为辅助药物应用，取得了有前景的结果，尽管其长期安全性需要进一步研究。然而，在颌面创伤中，其应用仅限于大型缺损的修复。安全问题包括术后水肿以及理论上的致癌风险。虽然术后水肿是可控的，但rhBMP-2与癌症之间的联系仍不清楚。局限性包括缺乏理想的载体、rhBMP-2成本高昂以及缺乏最佳给药方案。总之，rhBMP-2是一种有前景的颌面外科移植材料。然而，由于安全性和成本问题，它尚未成为金标准。需要进一步研究以确定其长期安全性、优化给药剂量并开发更好的载体。
